<DOC>
	<DOCNO>NCT02064777</DOCNO>
	<brief_summary>Our first aim thus investigate , retrospectively first prospectively , de novo pediatric ( live donor ) liver recipient , tacrolimus vivo vitro metabolism variability focus pharmacokinetics , pharmacodynamics , pharmacogenomics evolution accord age transplant delay . Our second aim find good tacrolimus exposure marker therapeutic drug monitoring ( TDM ) Area Under time-concentration Curve ( AUC ) intralymphocytic ( PBMCs ) tacrolimus concentration way model predict without invasive test pediatric patient . The final objective implement finding individualize comprehensive immunosuppression protocol monitor order maintain adequate well-balanced immunosuppression ( prevent graft rejection avoid acute long-term side effect ) . This particularly important pediatric population expose throughout life immunosuppressant .</brief_summary>
	<brief_title>Prospective Tacrolimus Pharmacokinetics Study Pediatric Living Donor Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Children age 0 18 year First Liver transplantation Children eligible receive tacrolimus post transplantation Consent parent Multiorgan transplantation Retransplantation ABO incompatible donor ( unless recipient &lt; 1 year antiAB antibody &lt; 1/32 ) Multi organ failure Need additionnal therapy except methylprednisolone treat rejection Intravenous tacrolimus First tacrolimus administration postpone day 3</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>